A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

NCT07230106 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

218

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: HS-20093 for Injection
DRUG: SHR3680 Tablet
DRUG: Abiraterone Tablet
DRUG: SHR2554 Tablet
DRUG: Enzalutamide Tablet
DRUG: Darotamine Capsule

Sponsor

Jiangsu HengRui Medicine Co., Ltd.